Arslan Liaqat/LinkedIn
Aug 8, 2026, 06:51
Arslan Liaqat: New Data on Iron Chelation in Thalassemia
Arslan Liaqat, Doctor of Medicine at BBH Rawalpindi, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in LMJHCR, adding:
“Excited to share the executive summary of our RCT on Deferasirox vs. Deferoxamine in Transfusion-Dependent Thalassemia (published in LMJHCR)!”
Title: Evaluating Effectiveness of Deferasirox Versus Deferoxamine in Improving Clinical Outcomes among Patients with Transfusion-Dependent Thalassemia: A Randomized Controlled Trial
Authors: Muhammad Mohsin Shoukat, Hafiza Khadija Tariq, Fareed Ullah, Muhammad Arslan Liaqat, Areeba Sajjad, Nauman Akhtar
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke